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Results at 2 Years after Gene Therapy for
RPE65-Deﬁcient Leber Congenital Amaurosis
and Severe Early-ChildhoodeOnset Retinal
Dystrophy
Richard G. Weleber, MD,1 Mark E. Pennesi, MD, PhD,1 David J. Wilson, MD,1 Shalesh Kaushal, MD, PhD,2
Laura R. Erker, PhD,1 Lauren Jensen, MS, RN,1 Maureen T. McBride, BS,1 Terence R. Flotte, MD,3
Margaret Humphries, RN,2 Roberto Calcedo, PhD,5 William W. Hauswirth, PhD,4 Jeffrey D. Chulay, MD,6
J. Timothy Stout, MD, PhD1
Purpose: To provide an initial assessment of the safety of a recombinant adeno-associated virus vector
expressing RPE65 (rAAV2-CB-hRPE65) in adults and children with retinal degeneration caused by RPE65
mutations.
Design: Nonrandomized, multicenter clinical trial.
Participants: Eight adults and 4 children, 6 to 39 years of age, with Leber congenital amaurosis (LCA) or
severe early-childhoodeonset retinal degeneration (SECORD).
Methods: Patients received a subretinal injection of rAAV2-CB-hRPE65 in the poorer-seeing eye, at either of
2 dose levels, and were followed up for 2 years after treatment.
Main Outcome Measures: The primary safety measures were ocular and nonocular adverse events.
Exploratory efﬁcacy measures included changes in best-corrected visual acuity (BCVA), static perimetry central
30 visual ﬁeld hill of vision (V30) and total visual ﬁeld hill of vision (VTOT), kinetic perimetry visual ﬁeld area, and
responses to a quality-of-life questionnaire.
Results: All patients tolerated subretinal injections and there were no treatment-related serious adverse
events. Common adverse events were those associated with the surgical procedure and included subconjunctival
hemorrhage in 8 patients and ocular hyperemia in 5 patients. In the treated eye, BCVA increased in 5 patients, V30
increased in 6 patients, VTOT increased in 5 patients, and kinetic visual ﬁeld area improved in 3 patients. One
subject showed a decrease in BCVA and 2 patients showed a decrease in kinetic visual ﬁeld area.
Conclusions: Treatment with rAAV2-CB-hRPE65 was not associated with serious adverse events, and
improvement in 1 or more measures of visual function was observed in 9 of 12 patients. The greatest improvements in
visual acuity were observed in younger patients with better baseline visual acuity. Evaluation of more patients and a
longer duration of follow-up will be needed to determine the rate of uncommon or rare side effects or safety
concerns. Ophthalmology 2016;123:1606-1620 ª 2016 by the American Academy of Ophthalmology. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material is available at www.aaojournal.org.
RPE65 is a 65-kDa isomerohydrolase produced by retinal
pigment epithelium cells that catalyzes a key step in the
conversion of all-trans-retinyl ester to 11-cis retinol, a step
essential in regenerating the visual chromophore.1,2 Muta-
tions of RPE65 result in a profound deﬁciency of the active
chromophore. Most patients with mutations of RPE65 have
Leber congenital amaurosis (LCA), a heterogeneous
disorder that presents in infancy with profound visual
impairment, nystagmus, weakly reactive pupils, and a range
of fundus appearances that can evolve from initially normal
appearance to severe pigmentary changes.3 The
electroretinogram (ERG) results are profoundly abnormal
in most forms of LCA and may be unrecordable over the
noise level.4 A minority of patients with RPE65 mutations
seek treatment after infancy, but still within the ﬁrst
decade of life, with similar but initially milder symptoms
dominated by night blindness. This phenotype has been
referred to by a number of names, including early-onset
retinitis pigmentosa,5,6 early-onset severe rodecone retinal
degeneration,7 and severe early-childhoodeonset retinal
dystrophy (SECORD).8 The ERG results are severely
abnormal in SECORD,8,9 but may still be recordable in
childhood, including in patients who have mutations in
RPE65.3,10,11 Mutations in RPE65 account for 6% to 16% of
cases of LCA12,13 and 2% of cases of autosomal recessive
retinitis pigmentosa or SECORD.14,15
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Proof-of-principle studies demonstrating the safety and
beneﬁt of gene replacement have been conducted in
murine16,17 and canine17e21 models of RPE65 deﬁciency
and in human patients, in whom RPE65 gene replacement
has successfully restored cone and rod sensitivity, improved
visual ﬁelds, and in some cases, improved visual
acuity.22e28 Improvement in visual function was reported to
persist for at least 3 years after treatment,29 despite
continuing retinal degeneration documented by optical
coherence tomography (OCT).30 More recent studies have
reported durable beneﬁt, but a reduction in the magnitude
of improvement, after a 5- to 6-year follow-up period31 or
during a 2-year follow-up period after administration of an
adeno-associated virus (AAV) vector that used a weaker
promoter.32 Herein, we report the results of a clinical trial
evaluating the safety and efﬁcacy of gene replacement
therapy in 12 patients with LCA or SECORD caused by
RPE65 mutations at 2 after subretinal injection of an
AAV RPE65 gene therapy vector.
Methods
The study was supported by a grant from the United States Food
and Drug Administration’s Ofﬁce of Orphan Products Develop-
ment and was conducted according to the tenets of the Declaration
of Helsinki. The protocol and Health Insurance Portability and
Accountability Act-compliant informed consent forms were
approved by institutional review boards, and each subject, or a
parent or guardian of patients younger than 18 years, gave written
informed consent. Pediatric subject assent was obtained as required
by institutional review boards. Study oversight was provided by an
independent data and safety monitoring committee. The study is
listed on ClinicalTrials.gov under identiﬁer NCT 00749957.
Study Design
This was an open-label, nonrandomized, multicenter, sequential,
2-arm, phase 1/2 clinical trial evaluating safety and efﬁcacy
parameters after subretinal injection of a recombinant AAV vector
expressing human RPE65 (rAAV2-CB-hRPE65). Safety was
monitored by evaluating adverse events, hematologic and clinical
chemistry parameters, and the presence of the vector in blood.
Efﬁcacy was assessed by evaluation of best-corrected visual acuity
(BCVA) and visual ﬁelds (primary efﬁcacy parameters), ERG
results, and quality-of-life questionnaire responses (secondary
efﬁcacy parameters). Additional outcome parameters included
OCT, ERG, and fundus photography.
Eligibility Criteria
Eligibility criteria included age of at least 6 years, retinal disease
consistent with LCA or SECORD and documented mutations in
both alleles of the RPE65 gene, BCVA not better than 20/60 and
not worse than hand movements in both the treated and fellow eye,
and visible photoreceptor (outer nuclear) layer on an OCT scan in
the region of the retina where the study agent administration was
planned.
Treatment
Vector design and production followed the methods of Jacobson
et al.33 A device compatibility study demonstrated no decrease in
vector titer after exposure to the 39-gauge microinjection cannula
(catalog no. 12.12; Synergetics, USA, O’Fallon, MO) used to
administer the vector. Patients were enrolled into 2 groups of 6 each.
For each subject, the poorer-seeing eye underwent a vitrectomy and
received a subretinal injection of 450 ml containing 1.8  1011
(group 1) or 6  1011 (group 2) vector genomes of rAAV2-CB-
hRPE65. For patients in group 1, the retinotomy used to administer
the vector was made outside the retinal vascular arcade. For patients
in group 2, the retinotomy was inside the vascular arcade. All pa-
tients received postoperative treatment with topical corticosteroids
and antibiotics.
Clinical Assessments
All patients underwent assessments of visual function at 14 spec-
iﬁed visits during the 2-year clinical trial. These included a
screening visit within 8 weeks of surgery, a 2-day baseline visit
before treatment that occurred on day 0, and posttreatment visits 1,
7, and 14 days; 1, 3, 6, and 9 months; and 1, 1.5, and 2 years after
treatment. At each visit, BCVA was measured using an electronic
visual acuity system34 based on the Early Treatment Diabetic
Retinopathy Study (ETDRS) method,35,36 and an ophthalmic
examination (slit-lamp retinal biomicroscopy, tonometry, and
indirect ophthalmoscopy) was performed.
Spectral-domain OCT imaging of both the treated and untreated
eye was performed with the Heidelberg Spectralis (Heidelberg
Engineering, Inc., Heidelberg, Germany). Horizontal and vertical
line scans were obtained through the foveal depression of each eye
at baseline and the year 1 visit. Automatic real-time eye tracking
was used when possible. Scans were segmented manually by a
grader (Peter Steinkamp) masked to the treatment eye with the
manufacturer’s provided software (HRA Spectralis viewing mod-
ule version 6.0.9.0; Heidelberg Engineering, Inc.). Three retinal
boundaries were delineated: the internal limiting membrane, the
inner boundary of the outer plexiform layer, and Bruch’s mem-
brane. The location of minimum foveal thickness was marked. The
coordinates of the linear segmentation were aligned at the central
fovea location with a custom program written in MATLAB
(version 8.2 (R2013b); MathWorks, Inc., Natick, MA). The data
were standardized along the lateral scale and were processed in
Excel (Excel 2013; Microsoft Corporation, Redmond, WA). A
6000-mm width of each scan was analyzed. Three layer thicknesses
were determined: inner retina (deﬁned as the distance between the
internal limiting membrane and the outer plexiform layer), outer
retina (deﬁned as the distance between the outer plexiform layer
and Bruch’s membrane), and total retina thickness.
Semiautomated kinetic perimetry (SKP) and full-ﬁeld static
perimetry were performed on 3 occasions before treatment and at
posttreatment visits 14 days; 1, 3, and 6 months; and 1 and 2
years after treatment using the Octopus 101 perimeter (Haag-
Streit, Koeniz, Switzerland) as described previously.8 Static
perimetry used the GATEi strategy (Haag-Streit AG, Köniz,
Switzerland)37,38, stimulus size V, and a radially designed, cen-
trally condensed grid of 148 test locations that extended to 54
superiorly, 78 nasally and inferiorly, and 80 temporally. The
set of x, y, and z examination data, where x and y are the Car-
tesian coordinates of the test location and z is the threshold
level, was exported from the perimeter and the threshold values
converted to differential luminous sensitivity values using a
published transformation formula.39 The sensitivity values
were imported for topographical display and volumetric
analysis into a software application, Visual Field Modeling
and Analysis, or VFMA (Ofﬁce of Technology Transfer &
Business Development [OHSU], Portland, OR). Once in the
application, the sensitivity data were ﬁt in non-Euclidian space
with a thin-plate, radial-based spline, creating a 3-dimension
model of the hill of vision.40 The magnitude and extent of
sensitivity was quantiﬁed in decibel-steradian (dB-sr) units by
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interpolating the volume beneath the surface of the thin-plate
spline representation of the hill of vision. The total volume of
the entire hill of vision (VTOT) was determined using a selection
process that conformed to the external boundary of the test grid.
The central 30 portion of the hill of vision (V30) was measured
by a circle of 30 radius as a separate metric of the central portion
of the visual ﬁeld. The details of this type of analysis have been
published previously.39
Normative Study of Static and Kinetic Perimetry
A normative visual ﬁeld study, approved by the Institutional
Review Board of Oregon Health & Sciences University, was
conducted at the Casey Eye Institute using the Octopus 101 for
both semiautomated kinetic perimetry and static perimetry.
Informed consent was obtained for adults and both parental consent
and assent of the individual were obtained for children. Normal
subjects were tested once with SKP, with static perimetry using the
148-point test grid and stimulus size V, or with both. Static peri-
metry testing in 1 child (a 7-year-old girl) and testeretest vari-
ability of SKP in 2 children (an 8-year-old boy and a 9-year-old
girl) also were evaluated. Results of testing in normal patients and a
discussion are provided in the Supplemental Material (available at
www.aaojournal.org).
Electroretinography
Full-ﬁeld ERGs were recorded before and 6 and 12 months after
treatment as described previously41,42 and according to International
Society for Clinical Electrophysiology of Vision (ISCEV) stan-
dards43,44 with the following modiﬁcations. All patients were dark
adapted for at least 30 minutes. For dim scotopic stimuli, a series of
ﬂashes were deliveredmeasuring3.2,2.6,2.0,1.6,0.6, 0.0,
and 0.6 log cd-s/m2. One subject required sedation for ERG
recordings, which were performed as previously described.45 Vision-
related quality of life was analyzed according to the National Eye
Institute 25-Item Visual Function Questionnaire (NEI-VFQ-25).46
Samples for hematologic, clinical chemistry, and urinalysis
testing were obtained at the screening visit, at the baseline visit,
and at visits 1, 7, and 14 days and 3 months after treatment. Serum
to measure neutralizing antibodies to wild-type AAV47 was
obtained at the screening visit and at visits 14 days and 1 and 3
months after treatment. Peripheral blood mononuclear cells to
measure T-cell responses to AAV2, the serotype used to create
the vector used for this clinical trial, and RPE65 peptides by
enzyme-linked immunospot assay48 were obtained at the
screening visit, at the baseline visit, and at visits 1, 2, and 3
months after treatment. Whole blood for detection of vector
DNA by polymerase chain reaction assay49 was obtained at the
screening visit and at visits 1, 7, and 14 days after treatment.
Statistical Methods
Each of the 12 patients underwent 2 pretreatment visual acuity tests
for each eye. The coefﬁcient of repeatability was determined using
the method of Bland and Altman50 for all eyes and for 19 eyes after
excluding 5 eyes that had an ETDRS letter score of 0 for both tests.
Each of the 12 patients underwent 3 pretreatment (baseline) static
and kinetic perimetry tests for each eye. For V30 and VTOT, the
limits of agreement among baseline tests for all patients were
calculated pairwise between each of the baseline results,
incorporating data for both eyes for all patients. The difference
between the average baseline value for each subject and each
posttreatment value for that subject then was determined and
compared with the upper and lower limit of agreement as the
criteria that would represent a statistically meaningful change for
a subject.51 Results for 6 of 72 baseline tests and 7 of 168
posttreatment tests that had a false-positive rate of more than
25% were excluded from this analysis. For kinetic visual ﬁelds, the
mean  standard deviation of the total area with the V4e target was
determined for the 3 pretreatment tests and was compared with the
results at each subsequent visit.
Results
Twelve patients, 6 to 39 years of age, with DNA sequence-conﬁrmed
mutations in RPE65were enrolled, 10 at the Casey Eye Institute and
2 at the University of Massachusetts, between July 2009 and
September 2012. Baseline characteristics of these patients are shown
in Table 1. RPE65 mutations were compound heterozygous in 9
patients and homozygous in 3 patients. The genotype was unique
in all patients except 2 brothers (patients 202 and 203).
Pretreatment BCVA in the worse eye was between 40 and 62
ETDRS letters (0.90e0.46 logarithm of the minimum angle of res-
olution [logMAR]) in the 4 children, between 20 and 31 ETDRS
letters (1.30e1.12 logMAR) in 3 adults, and countingﬁngers or hand
movements in 5 other adults. The difference between the better eye
and worse eye before treatment ranged fromþ2.5 toþ13.5 letters in
the 4 pediatric patients and 0 to þ5 letters in the 8 adult patients.
The ﬁrst 6 patients received a dose of 1.8 1011 vector genomes
per eye and the second 6 patients received a dose of 6 1011 vector
genomes per eye, administered by subretinal injection in a volume of
0.45ml. The subretinal bleb included the fovea in 5 patients (patients
205, 206, 207, 208, and 210), and 1 subject (patient 204) received
the 0.45-ml dose divided between 2 injection sites (Fig 1).
Safety Evaluations
All patients tolerated the surgery and study agent administration
with no treatment-related serious adverse events. The most com-
mon adverse events were those associated with the surgical pro-
cedure and included subconjunctival hemorrhage in 8 patients;
ocular hyperemia in 5 patients; reduced visual acuity, eye pain, eye
irritation, increased intraocular pressure, headache, or back pain in
2 patients each; and abnormal sensations in the eye or reduced
visual acuity in 1 subject each. All of these were mild to moderate
in intensity and generally resolved within 1 to 30 days. Adverse
events considered possibly related to the rAAV2-CB-hRPE65
study agent were ocular hyperemia in 2 patients and photopsia in 1
subject. A list of all adverse events is provided in Supplemental
Table S1 (available at www.aaojournal.org).
One serious adverse event occurred in this study. Noncardiac
chest pain and hypertension developed in patient 201 at the year 1
follow-up visit that resulted in overnight hospitalization, was
considered not related to study agent, and resolved within 1 day.
Patient 205 had dispersion of subretinal pigment within the sub-
retinal bleb during study agent administration that was associated
with persistent reduction in BCVA and mild reduction of visual ﬁeld
measures in the treated eye, but by the end of the study, he reported
that the treated eye was the better-seeing eye in dim illumination.
This subject also had a persistent elevation of intraocular pressure
(41 mmHg on day 8) that responded to conventional management
with topical dorzolamide and timolol for 7 weeks. In 3 patients, a
small amount of subretinal ﬂuid was detected in the treated eye on
OCT examination 1 day after surgery that resolved by the next visit
(patients 204 and 206) or by the month 2 visit (patient 201). Anterior
chamber cells of grade 0.5 (1e5 cells per ﬁeld) were observed at
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Table 1. Baseline Demographic, Genetic, and Clinical Characteristics of 12 Patients with RPE65 Leber Congenital Amaurosis or Severe Early-ChildhoodeOnset Retinal Dystrophy
Patient
No. Age (yrs) Gender Race Ethnicity RPE65 Genotype
Visual Acuity* Visual Field
National Eye Institute
25-Item Visual Function
Questionnaire ScorexBetter Eye Worse Eye Kinetic (deg2)y
Static (Decibel-Steradian)z
Total Visual Field Hill
of Vision
Central 30 Visual Field
Hill of Vision
301 39 Male White Non-Hispanic Gly40Ser His182Tyr 5 0 (HM) 558 3.5 1.4 54
201 33 Female Black Non-Hispanic Arg124Stop Tyr318Asn 23.5 20.5 14 727 44.4 5.2 31
303 35 Male Black Non-Hispanic Arg124X Trp402X 6.5 2.5 (CF) 1038 3.6 0.7 54
202 6 Male White Hispanic Arg118Ser Val443Ala 53.5 40 14 408 29.4 9.0 75
203 11 Male White Hispanic Arg118Ser Val443Ala 63.5 57.5 13 738 33.0 8.9 69
204 6 Female White Non-Hispanic Tyr368His Tyr431His 57.5 48 11009 27.9 8.7 55
205 37 Male White Hispanic Arg124Stop Arg91Gln 33 31 181 6.8 28 57
206 30 Female Asian Non-Hispanic c289dupA c289dupA 0 (CF) 0 (CF) 51 1.0 0.8 45
207 32 Female White Hispanic c.1336dupA c.1336dupA 4.5 1 (CF) 1144 7.0 2.9 48
208 28 Female White Hispanic Tyr144 stop Asn451Tyr 30 25.5 14 050 21.1 6.8 36
209 35 Female Asian Non-Hispanic H182R H182R 0 (HM) 0 (HM) 1086 6.5 1.9 50
210 6 Male White Non-Hispanic Lys294ins1gacA Ala415Val 64.5 62 9448 18.4 5.7 76
CF ¼ counting ﬁngers; HM ¼ hand movements.
Patients are listed in the order in which they entered the trial.
*Mean of 2 pretreatment Early Treatment Diabetic Retinopathy Study letter scores.
yAverage area in square degrees for 3 pretreatment tests in the treated eye with a V4e target.
zAverage retinal sensitivity in decibel-steradians for 3 pretreatment tests in the treated eye for the total or central 30 ﬁeld.
xComposite score, for which the maximum score is 100.
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days 1 and 7 in patient 210 and at day 14 in patients 208 and 209. No
other patients showed signs of ocular inﬂammation, and no patients
demonstrated prolonged retinal detachment, vitreous hemorrhage,
or development of a cataract.
There were no clinically important changes in hematologic or
serum chemistry parameters after study agent administration. Titers
of neutralizing antibodies to AAV increased in 5 of 12 patients,
including 1 of 4 children and 4 of 8 adults (see Supplemental
Table S2, available at www.aaojournal.org). No patient
demonstrated an enzyme-linked immunospot response to RPE65
or AAV2 capsid peptides and no patient had vector DNA detected
in blood at any time point tested.
Visual Acuity
Results of visual acuity testing over time are presented in Figure 2.
The repeatability coefﬁcient was 0.145 logMAR, equivalent to 7
ETDRS letters, for all eyes, and 0.164 logMAR, equivalent to 8
ETDRS letters, for the 19 eyes that had an ETDRS letter score of
more than 0 on both pretreatment tests. (One subject had count
ﬁngers at both pretreatment tests, with an ETDRS letter score of
0 on one test and 1 on the other.). In the treated eye, BCVA did
not change in the 5 patients with counting ﬁngers or hand
movements vision, but decreased immediately after treatment as a
result of surgical elevation of the retina in the other 7 patients. In
6 patients, BCVA improved to pretreatment levels or more by day
14 (patients 202 and 204), month 1 (patients 201, 203, and 210),
or month 2 (patient 208). In 5 of these patients, improvement in
BCVA compared with pretreatment BCVA persisted during the 2-
year study and was greater in the treated eye than in the untreated
eye (Fig 3). In patient 205, BCVA in the treated eye remained at less
than pretreatment levels throughout the 2-year study. In patient 208,
there was worsening of BCVA during the second year of the study in
both the treated and untreated eye, with a loss of 24.5 letters in the
treated eye and 14 letters in the untreated eye at the year 2 visit
compared with baseline.
Optical Coherence Tomography Analysis
Because of advanced degeneration in some patients, OCT seg-
mentation was difﬁcult and could be completed in both eyes of
only 6 patients (patients 202, 203, 204, 205, 208, and 210). After
treatment, the outer retinal thickness was increased variably or
decreased at different eccentricities from the fovea. Both treated
and untreated eyes demonstrated changes in thickness; however,
the patterns were quite variable and there was neither evidence
suggestive of a treatment effect, nor for a toxic effect. Interpreta-
tion of the data was limited by the overall poor quality of the data
primarily because of poor ﬁxation in these patients.
Static Perimetry
Results of analyses of static perimetry for all patients in the trial are
presented in Figures 4 and 5 and in Supplemental Table S3
(available at www.aaojournal.org). A graphic example of the
visual ﬁeld modeling and analysis results for patient 202 is shown
in Supplemental Figure S1 (available at www.aaojournal.org).
Figure 1. Images showing the locations of subretinal blebs after administration of recombinant adeno-associated virus vector expressing RPE65. The bleb
included the subfoveal area for patients 205, 206, 207, 208, and 210.
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There was more than a 10-fold variation among patients in the
average baseline retinal sensitivity determined by static perimetry,
which in the treated eye ranged from 0.67 to 9.03 dB-sr
(mean, 4.56 dB-sr; median, 1.42 dB-sr) for V30 and from 1.04 to
44.37 dB-sr (mean, 16.87 dB-sr; median, 3.58 dB-sr) for VTOT
(Table 1). Comparison of pretreatment values for V30 and VTOT
found no signiﬁcant between-test differences. The average limit
of agreement for all baseline retinal sensitivity results was 3.50
to þ3.12 dB-sr for V30 and 9.73 to þ8.17 dB-sr for VTOT.
Six patients (patients 202, 203, 204, 207, 208, and 210) showed
improvement in V30 in the treated eye at 1 or more posttreatment
visits, and 4 of these patients (patients 202, 207, 208, and 210) also
showed improvement in V30 in the untreated eye at 1 or more
posttreatment visits (Fig 4; Supplemental Table S3, available at
www.aaojournal.org). Five patients (patients 202, 204, 207, 208,
and 210) showed improvement in VTOT in the treated eye at 1 or
more posttreatment visits, and 3 of these patients (patients 202,
207, and 210) also showed improvement in VTOT in the
untreated eye at 1 or more posttreatment visits (Fig 5;
Supplemental Table S3, available at www.aaojournal.org).
One patient (patient 204) showed a decrease in V30 in the
treated eye at a single posttreatment visit and 2 patients (patients
202 and 208) showed a decrease in V30 in the untreated eye at 1 or
2 posttreatment visits (Fig 4; Supplemental Table S3, available at
www.aaojournal.org). Four patients (patients 201, 203, 204, and
208) showed a decrease in VTOT in the treated eye at 1 or more
posttreatment visits, and 3 patients (patients 202, 203, and 208)
showed a decrease in VTOT in the untreated eye at 1 or more
posttreatment visits (Fig 5; Supplemental Table S3, available at
www.aaojournal.org).
Kinetic Perimetry
There was more than a 100-fold variation among patients in the
average baseline kinetic visual ﬁeld area, which for the V4e target
ranged from 51 to 14 727 deg2 (mean, 7308 deg2; median, 5296
deg2) in the treated eye (Table 1). Four patients showed
improvement in kinetic visual ﬁelds during the study (Fig 6).
Patients 301, 303, and 207 showed an increase in kinetic visual
ﬁeld area in the treated eye compared with baseline at the month 6
and year 1 and 2 visits, with a decrease in visual ﬁeld area in the
untreated eye at the month 6 and year 1 and 2 visits in patient 303
and at the year 2 visit in patient 301 (Table 2). Patient 201 showed
resolution of a central scotoma on kinetic testing in the treated eye
(Fig 6). Although this was not more that the limit of agreement of
pretreatment values, she also showed a modest increase in V30
decibel-steradian units on static perimetry and reported improve-
ment in her ability to navigate independently when traveling through
airports. Two patients showed worsening of kinetic visual ﬁelds
during the study (Fig 7). Patient 209 showed a loss of kinetic visual
ﬁeld area in the treated eye compared with baseline at the month 6
and year 1 and 2 visits, with an increase in visual ﬁeld area in the
untreated eye at these visits, and patient 208 showed a substantial
decrease in the kinetic visual ﬁeld area in both eyes during the
study that was larger in the treated eye than in the untreated eye
(Table 2). The other 6 patients had no apparent changes in kinetic
visual ﬁeld area with the V4e target. Changes in kinetic visual
ﬁeld area with the V4e target for all patients are displayed in
Supplemental Figure S2 (available at www.aaojournal.org).
Patient 205 showed a small increase in kinetic visual ﬁeld area
with the II4e target, from a mean  standard deviation of 42
deg2 before treatment to 25.4 deg2, 39.8 deg2, and 40.8 deg2 at the
month 6, year 1, and year 2 visits, respectively. None of the other
patients had any apparent changes in kinetic visual ﬁeld area with
the III4e or II4e targets.
Normative Data for Static and Kinetic Perimetry
Fifteen normal controls (6 males and 9 females; mean age,
34.717.7 years) were tested using SKP and 13 normal controls
Figure 2. Graphs showing serial visual acuity measurements in patients treated with recombinant adeno-associated virus vector expressing RPE65 by
subretinal injection on day 0. Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 85 ¼ 0.00 logarithm of the minimum angle of resolution
(logMAR) ¼ Snellen 20/20. An ETDRS letter score of 35 ¼ 1.0 logMAR ¼ Snellen 20/200.
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Figure 3. Graphs showing visual acuity changes from baseline after subretinal injection of recombinant adeno-associated virus vector expressing RPE65 in 7
patients with pretreatment visual acuity better than counting ﬁngers. Each patient’s pretreatment visual acuity in the treated and untreated eye is in pa-
rentheses after the patient’s study number. Diamond symbols are for treated eyes, square symbols are for untreated eyes, open symbols are for the lower-dose
group, and solid symbols are for the higher-dose group. Changes from baseline in the treated and untreated eye at the year 2 visit are shown in the table at the
bottom of the ﬁgure.
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(4 males and 9 females; mean age, 38.919.6 years) were tested
using static perimetry. To evaluate whether the results obtained in
children younger than 18 years, and in particular those in the ﬁrst
decade of life, were comparable with those of adults, the SKP
values for the isopter areas (in square degrees) for target sizes V4e,
III4e, II4e, and I4e and the indices VTOT and V30 from static peri-
metry were graphed by age of testing (see Supplemental Figs S4
and S5, available at www.aaojournal.org). Further discussion of
the normative ﬁndings is presented in the Supplemental Materials
(available at www.aaojournal.org). The graphs of SKP isopter
areas ﬁt best with a linear equation with age and were reasonably
ﬂat except for possibly mild decline in later years. The values in
the children 10 years of age and younger appeared to be
consistent with the graph obtained over the entire range of adult
ages. The volumetric measures of VTOT and V30 derived from hill
of vision modeling appeared to ﬁt notably better using a quadratic
equation with smaller root mean square error (RMSE) values and
larger R2 values. The maximum peak of the equation that best ﬁt
the data was in the second to third decade of life. Again, the
volumetric measures of sensitivity for children in the ﬁrst and
second decades of life seemed comparable with those for young
adults.
Figure 4. Graphs showing central 30 visual ﬁeld hill of vision (V30) changes from baseline. The mean baseline V30 value in the treated and untreated eye is
listed after each patient number. Diamond symbols are for treated eyes, square symbols are for untreated eyes, open symbols are for the lower-dose group, and
solid symbols are for the higher-dose group. Asterisks indicate changes larger than the limit of agreement of pretreatment values for all patients.
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Electroretinography
Scotopic and photopic ERG responses were reduced severely in all
patients. In 8 of 12 patients, dim scotopic, bright scotopic, and
single ﬂash photopic responses were not recordable. A 30-Hz
ﬂicker response of amplitude 0.2 to 1.1 mV was discernible in 6
of these 8, but only after ﬁltering techniques to isolate the funda-
mental frequency. The meaningfulness of these submicrovolt
responses is questionable. None of these 8 patients demonstrated a
convincing increase in the ERG responses in either eye after
treatment.
Four patients (patients 201, 202, 203, and 204) had small but
recordable ERG responses during the study (Supplemental
Table S4, available at www.aaojournal.org). For the 30-Hz
ﬂicker response, patient 203 showed no changes in either eye
after treatment, patient 201 showed a decrease in the treated
eye with no change in the untreated eye, and patients 202 and
204 showed an increase in the treated eye that was more than that
in the untreated eye. Patient 204 also demonstrated small
but recordable a- and b-waves to the brightest stimuli under
scotopic and photopic conditions (Fig 8). At the month 12 visit,
Figure 5. Graphs showing total visual ﬁeld hill of vision (VTOT) changes from baseline. The mean baseline VTOT value in the treated and untreated eye is
listed after each subject number. Diamond symbols are for treated eyes, square symbols are for untreated eyes, open symbols are for the lower-dose group, and
solid symbols are for the higher-dose group. Asterisks indicate changes greater than the limit of agreement of pretreatment values for all patients.
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there was an increase in the scotopic b-wave amplitude (from 9
to 17 mV) in the treated eye compared with a decrease (from
15 to 11 mV) in the untreated eye, and the increase in the
photopic single ﬂash b-wave amplitude was slightly more in
the treated eye (from 5 to 13 mV) than in the untreated eye
(from 4 to 8 mV). The changes in photopic responses may
reﬂect intervisit variability, but the improvement in scotopic
recordings in the treated eye of patient 204 could reﬂect a
functional improvement.
Quality-of-Life Assessment
The NEI-VFQ-25 composite scores at baseline ranged from 55 to
76 for the 4 pediatric patients with better visual acuity and from 31
to 57 for the 8 adult patients with worse visual acuity (Table 1).
The NEI-VFQ-25 composite score was improved at all or most
time points after treatment in 11 of 12 patients and worse at all time
points after treatment in patient 205 (Supplemental Fig S3,
available at www.aaojournal.org).
Figure 6. Kinetic visual ﬁelds in patients 301, 303, 207, and 201 before and 2 years after subretinal injection of recombinant adeno-associated virus vector
expressing RPE65. The right eye was treated in patients 301, 303 and 207 and the left eye was treated in subject 201, indicated by the ƒ symbol.
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Discussion
Results of this study conﬁrm that rAAV2-CB-hRPE65
delivered by subretinal injection had an acceptable safety
proﬁle and was associated with improvement in 1 or more
measures of visual function in 9 of 12 patients. However,
the visual function parameters that improved varied among
patients, and 2 patients showed a decrease in BCVA or
Table 2. Changes from Baseline Kinetic Visual Field Area after Treatment
Patient No.
301 303 207 208 209
Treated eye
Baseline 558  145 1038  119 1144  132 14 050  2219 1086  454
Month 6 1199 1380 3462 14 406 209
Year 1 1028 1386 2752 1201 9
Year 2 1330 1502 2683 2866 0
Untreated eye
Baseline 2047  277 1213  100 2837  2065 13 297  4346 773  133
Month 6 2708 466 4093 16 112 1451
Year 1 2011 484 2966 14 892 2074
Year 2 234 602 4386 6523 1241
Values are the kinetic visual ﬁeld area in square degrees tested with a V4e target for the 5 patients who showed a change from baseline. The baseline value for
each patient is the mean  standard deviation of 3 pretreatment test results. The other 7 patients showed no consistent changes in total kinetic visual ﬁeld
area after treatment.
Figure 7. Kinetic visual ﬁelds in patients 208 and 209 before and 6 months and 2 years after subretinal injection of recombinant adeno-associated virus
vector expressing RPE65. The left eye was treated in both patients, indicated by the ƒ symbol.
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visual ﬁeld area that was more in the treated eye than in the
untreated eye.
The 4 pediatric patients (patients 202, 203, 204, and 210)
with baseline BCVA of 40 to 63 ETDRS letters showed
improvement in BCVA, ranging from a 6- to 14-letter
increase in the treated eye at the 2-year visit (Fig 3), which
was more than the upper bound for intervisit variability of
7 or 8 ETDRS letters in 3 of the 4 patients. Visual acuity
improvement was evident as early as 2 weeks after
injection and often demonstrated progressive improvement
for 3 months after treatment before stabilizing. This may
correspond to transcriptional activation of the transgene in
the AAV vector and is consistent with temporal
observations after treatment in prior studies.22e24,26 These
4 patients also showed improvement in V30 and 3 showed
improvement in VTOT at 1 or more posttreatment visits, but
none showed improvement in kinetic perimetry area.
Clinical examination also revealed reduced nystagmus in
these patients after treatment.
Among the 3 adults with baseline BCVA of 20 to 30
ETDRS, changes in the treated eye included a 2.5-letter
increase in BCVA and loss of a central scotoma in patient
201; a 7-letter decrease in BCVA, a small increase in visual
ﬁeld area with the II4e target, and subjective improvement
in vision under dim light conditions in patient 205; and a
24-letter decrease in BCVA and kinetic perimetry area, but
with an increase in V30 and VTOT at some visits, in patient
208. Among the 5 adults with baseline visual acuity of
counting ﬁngers or hand movements (patients 301, 303,
206, 207, and 209), none showed a change in BCVA. Three
of these patients showed an increase, 1 showed a decrease,
and 1 showed no change in kinetic visual ﬁeld area in the
treated eye. Patient 207 showed a small increase in V30 and
VTOT at some visits.
In 3 of the 4 pediatric patients with an increase in visual
acuity after treatment, the subretinal bleb visualized at
surgery did not include the fovea, and the subretinal bleb in
patient 201 did not extend to the area of the central scotoma
that resolved after treatment. It is possible that the size of the
bleb increased in the ﬁrst few days after subretinal injection,
as has been described after subretinal injection of AAV
vectors in dogs,52 and expanded toward the fovea. The
edges of the subretinal bleb are visible for extended
periods in dogs and can be monitored over time, but in
humans, the edges of the bleb are not apparent after the
subretinal ﬂuid is absorbed.
The increase in the visual ﬁeld sensitivity in the untreated
eye of several patients is consistent with observations in at
least some of our patients that the visual acuity also
improved to some degree in the untreated eye (Fig 3), and
other investigators also have reported improvements in
visual function for the untreated eye in their clinical trials
of gene replacement therapy for RPE65-deﬁcient LCA.27
Nystagmus was a common ﬁnding in our patients, and in
several instances, the parents or examining physicians
noted a decrease in nystagmus after treatment. Previous
studies have reported that use of an opaque occluder for
the nontested eye during visual ﬁeld testing will bring out
a latent nystagmus component, leading to an increase in
the apparent nystagmus, whereas use of a semitranslucent
occluder can promote more stable ﬁxation, can eliminate
the retinal rivalry-based Ganzfeld blankout phenomenon,
can increase retinal visual ﬁeld sensitivity, and can improve
global perimetric indexes.53,54 These reports are consistent
with our experience that worsening of an existing
nystagmus is less likely when using the semitranslucent
occluder provided by Haag-Streit. A substantial portion of
the central nervous system is involved in eye tracking,
saccades, and ﬁxation stability, functions for which the eyes
and brain work as a single unit. Because a dampening in
nystagmus would be expected to produce an increase in
foveal ﬁxation time and a concomitant increase in viewing
stability at the locations of visual ﬁeld testing in each eye,
the improvement in visual acuity and visual ﬁeld sensitivity
Figure 8. Electroretinogram responses for each eye of subject 204 before (red) and after (blue) subretinal injection of recombinant adeno-associated virus
vector expressing RPE65 (rAAV2-CB-hRPE65) in the right eye. The scotopic single ﬂash b-wave amplitude at 12 months following treatment was notably
increased for the right eye and was essentially unchanged for the left eye. The photopic single ﬂash b-wave amplitude and 30 Hz ﬂicker responses were also
increased over baseline for the treated right eye and, to a lesser degree, increased in amplitude over baseline for the untreated left eye. The black vertical bar
for the single ﬂash responses and 30 Hz ﬂicker responses indicate the stimulus occurrence. The length of the black arrow above each train of ﬂicker responses
depicts the implicit time from the initial stimulus to the positive b-wave peak.
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in the treated eye in this way might have contributed to the
improvement in acuity in the untreated eye over time.
Because of the large variation in baseline visual function,
the small number of patients per group, and the differences in
the location of the site of vector administration, it is not
possible to draw meaningful conclusions about any potential
dose-related differences in safety or efﬁcacy or the effect of
subfoveal vector administration, which was reported to be
associated with a negative outcome in 1 previous study of
gene replacement therapy in patients with RPE65 muta-
tions,29 but not in patients in other studies.27,32 The
improvement in visual acuity in the 1 pediatric patient in the
higher-dose groupwho received a subfoveal injection (patient
210)was similar to the improvement in the 3 pediatric patients
in the lower-dose group who did not receive subfoveal in-
jections (patients 202, 203, and 204), and 3 of 6 patients with
improvement in V30, VTOT, or both (patients 207, 208, and
210) were in the higher-dose group and received a subfoveal
injection. The NEI-VFQ-25 composite scores improved in 11
of 12 patients, but interpretation of these results is hindered by
the lack of an untreated control group.
In summary, analysis of results from this clinical trial
shows that AAV2-mediated RPE65 gene replacement ther-
apy generally was safe and was associated with improve-
ment in at least 1 measure of visual function in most
individuals with LCA or SECORD caused by RPE65 mu-
tations. There was a trend for this improvement to be
clustered in the younger patients, suggesting that treatment
at an early age may prevent progression of photoreceptor
degeneration.55e59 Evaluation of more patients and a longer
follow-up will be needed to determine the rate of uncommon
or rare side effects or safety concerns.
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